Literature DB >> 15133814

Drug adherence in Parkinson's disease.

Norman A Leopold1, Marcia Polansky, Marcia R Hurka.   

Abstract

Physicians modify drug schedules in response to their patients' clinical responses. Failure to relieve patients' symptoms or the emergence of drug-related side effects may reflect nonadherence to a prescribed drug schedule rather than incorrect therapeutic physician decisions. Using a medication questionnaire and a computerized medication event monitoring system (MEMS) to monitor medication use, nonadherence of drug use was examined in subjects with Parkinson's disease (PD). We report that prescription nonadherence in PD subjects was common and approximated that reported in other chronic diseases. During a 28-day observation period, only 4 of 39 subjects had complete schedule adherence, i.e., no missed, extra, or mistimed doses. Using a questionnaire, 24.3% of subjects acknowledged missing any doses but the computerized MEMS recorded that 51.3% of subjects missed at least one dose per week and 20.5% of subjects missed three or more doses per week. Mistiming of doses was admitted by 73% of subjects but 82.1% had recorded mistimed doses. Of multiple sociodemographic and disease-related items examined, only gender and level of education were statistically related to nonadherence. Copyright 2004 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133814     DOI: 10.1002/mds.20041

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  39 in total

1.  Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.

Authors:  Matthias Löhle; Heinz Reichmann
Journal:  BMC Neurol       Date:  2011-09-22       Impact factor: 2.474

Review 2.  Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices.

Authors:  Lizheng Shi; Jinan Liu; Yordanka Koleva; Vivian Fonseca; Anupama Kalsekar; Manjiri Pawaskar
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands.

Authors:  Job F M van Boven; Annoesjka Novak; Maurice T Driessen; Cornelis Boersma; Maarten M Boomsma; Maarten J Postma
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

Review 4.  Medication nonadherence in Parkinson's disease.

Authors:  Jori E Fleisher; Matthew B Stern
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

5.  Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry.

Authors:  Dongni Johansson; Anders Ericsson; Anders Johansson; Alexander Medvedev; Dag Nyholm; Fredrik Ohlsson; Marina Senek; Jack Spira; Ilias Thomas; Jerker Westin; Filip Bergquist
Journal:  CNS Neurosci Ther       Date:  2018-01-25       Impact factor: 5.243

Review 6.  A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence.

Authors:  Mohamed El Alili; Bernard Vrijens; Jenny Demonceau; Silvia M Evers; Mickael Hiligsmann
Journal:  Br J Clin Pharmacol       Date:  2016-05-02       Impact factor: 4.335

7.  Using n-of-1 trials as a clinical tool to improve prescribing.

Authors:  C Jane Nikles; Alexandra M Clavarino; Chris B Del Mar
Journal:  Br J Gen Pract       Date:  2005-03       Impact factor: 5.386

8.  Medication management and neuropsychological performance in Parkinson's disease.

Authors:  Kevin J Manning; Christina Clarke; Alan Lorry; Daniel Weintraub; Jayne R Wilkinson; John E Duda; Paul J Moberg
Journal:  Clin Neuropsychol       Date:  2011-12-12       Impact factor: 3.535

Review 9.  Challenges of treatment adherence in older patients with Parkinson's disease.

Authors:  Jacquelyn L Bainbridge; J Mark Ruscin
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

10.  Long-term retention rate of pramipexole in the treatment of Parkinson's disease.

Authors:  Tapani Keränen; Mervi Tuhkasaari; Hanna Kuusisto
Journal:  Eur J Clin Pharmacol       Date:  2009-05-05       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.